Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?
作者信息
Farnier Michel
机构信息
Department of Cardiology, CHU Dijon Bourgogne, and Lipid Clinic, Point Medical, Dijon, France.
出版信息
Ann Transl Med. 2018 Feb;6(3):60. doi: 10.21037/atm.2018.01.02.
Abstract
摘要
相似文献
1
Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?在接受胰岛素治疗的糖尿病患者中通过抑制前蛋白转化酶枯草溶菌素9降低低密度脂蛋白胆固醇：是否有效且安全？
Ann Transl Med. 2018 Feb;6(3):60. doi: 10.21037/atm.2018.01.02.
2
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.口服生物利用的大环肽，抑制 PCSK9 与低密度脂蛋白受体的结合。
Circulation. 2023 Jul 11;148(2):144-158. doi: 10.1161/CIRCULATIONAHA.122.063372. Epub 2023 May 1.
3
Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia.新型四氢原小檗碱衍生物（THPBs）作为前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）调节剂用于治疗高脂血症的设计、合成及生物学评价
Acta Pharm Sin B. 2019 Nov;9(6):1216-1230. doi: 10.1016/j.apsb.2019.06.006. Epub 2019 Jun 25.
4
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.阿托伐他汀、胆固醇酯转移蛋白抑制和糖尿病对高心血管风险患者循环前蛋白枯草溶菌素 9 和脂蛋白(a)水平的影响。
J Clin Lipidol. 2018 Jan-Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12.
5
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).依洛尤单抗降低低密度脂蛋白胆固醇水平及外周动脉疾病患者的结局：来自 FOURIER 试验（在高风险人群中用 PCSK9 抑制剂进行进一步心血管结局研究）的见解。
Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13.
6
PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).前蛋白转化酶枯草溶菌素9（PCSK9）抑制作用：发现、当前证据以及对低密度脂蛋白胆固醇（LDL-C）和脂蛋白(a) [Lp(a)]的潜在影响
Cardiovasc Drugs Ther. 2015 Jun;29(3):295-308. doi: 10.1007/s10557-015-6588-3.
7
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.以 PCSK9 为靶点，降低低密度脂蛋白胆固醇：一种有前途的新机制。
Pharmacol Ther. 2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. Epub 2016 Apr 29.
8
Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.在心血管风险较高的患者中，循环中的前蛋白转化酶枯草溶菌素9（PCSK9）水平与核磁共振评估的致动脉粥样硬化性血脂异常呈正相关。
Clin Sci (Lond). 2015 Jun;128(12):877-82. doi: 10.1042/CS20140832.
9
PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells.PCSK9 抑制与胰岛素分泌β细胞中的胆固醇稳态。
Lipids Health Dis. 2022 Dec 16;21(1):138. doi: 10.1186/s12944-022-01751-6.
10
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).AMG 145，一种针对 PCSK9 的单克隆抗体，可帮助高危患者实现国家胆固醇教育计划成人治疗专家组 III 低密度脂蛋白胆固醇目标：来自 LAPLACE-TIMI 57 试验的分析（使用 PCSK9 单克隆抗体抑制联合他汀类药物治疗进行 LDL-C 评估 - 心肌梗死溶栓治疗 57）。
J Am Coll Cardiol. 2014 Feb 11;63(5):430-3. doi: 10.1016/j.jacc.2013.09.048. Epub 2013 Oct 23.
本文引用的文献
1
Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.伴有或不伴有糖尿病的人群使用阿利西尤单抗的安全性：来自 14 项 ODYSSEY 试验的汇总数据。
Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9.
2
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years.前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂与 2 型糖尿病发病风险：一项超过 96000 患者年的系统回顾和荟萃分析。
Diabetes Care. 2018 Feb;41(2):364-367. doi: 10.2337/dc17-1464. Epub 2017 Nov 27.
3
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.在有和没有糖尿病的患者中，PCSK9 抑制剂依洛尤单抗的心血管安全性和疗效，以及依洛尤单抗对血糖和新发糖尿病风险的影响： FOURIER 随机对照试验的预先指定分析。
Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15.
4
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.在 1 型或 2 型糖尿病合并高心血管风险且接受胰岛素治疗的患者中，阿利西尤单抗的疗效和安全性：ODYSSEY DM-INSULIN 随机试验。
Diabetes Obes Metab. 2017 Dec;19(12):1781-1792. doi: 10.1111/dom.13114. Epub 2017 Oct 10.
5
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.阿利西尤单抗治疗 1 型或 2 型糖尿病伴高心血管风险的胰岛素治疗患者的疗效和安全性：ODYSSEY DM-INSULIN 试验的原理和设计。
Diabetes Metab. 2017 Oct;43(5):453-459. doi: 10.1016/j.diabet.2017.01.004. Epub 2017 Mar 24.
6
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.Bococizumab 在高危患者中的心血管疗效和安全性。
N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17.
7
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.阿利西尤单抗在有或无糖尿病患者中的降脂疗效和安全性：ODYSSEY COMBO II 的一项亚组分析。
Diabetes Obes Metab. 2017 Jul;19(7):989-996. doi: 10.1111/dom.12909. Epub 2017 Apr 18.
8
9. Cardiovascular Disease and Risk Management.9. 心血管疾病与风险管理。
Diabetes Care. 2017 Jan;40(Suppl 1):S75-S87. doi: 10.2337/dc17-S012.
9
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.载脂蛋白 B 代谢关键基因 PCSK9 和 HMGCR 变异与心血管疾病和糖尿病风险
N Engl J Med. 2016 Dec 1;375(22):2144-2153. doi: 10.1056/NEJMoa1604304.
10
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.载脂蛋白 B 代谢途径基因变异与 2 型糖尿病风险：一项孟德尔随机化研究。
Lancet Diabetes Endocrinol. 2017 Feb;5(2):97-105. doi: 10.1016/S2213-8587(16)30396-5. Epub 2016 Nov 29.
Zotero 插件